INTRODUCTION {#S7}
============

Osteoporosis is a disease characterized by low bone mass and compromised bone structure, and an increased fracture risk ([@R1]). Sublesional osteoporosis is a disease process unique to person with SCI, associated with regional declines in hip and knee region bone mass, alterations in bone structure and an increased propensity for fragility fracture of the distal femur, proximal tibia and hip regions ([@R2]). The prevalence of sublesional osteoporosis (SLOP) in the SCI population is estimated to be as high as 82% ([@R3], [@R4]), with fracture occurrence double that of the non-SCI population ([@R5]). Furthermore, 25--34% of individuals with SCI are reported to have sustained at least one lower extremity fracture since their SCI ([@R4], [@R6]). Low trauma fractures in the SCI population occur during activities of daily living, and often require hospitalization, resulting in further immobility ([@R7]).

Vitamin D deficiency and secondary hyperparathyroidism may contribute to the development of osteoporosis in SCI ([@R8]). The prevalence of vitamin D deficiency in the SCI population has been estimated as high as 93% ([@R9]). Additionally, one-third of individuals with chronic SCI demonstrated serum 25(OH)D levels less than the normal range, and had associated secondary hyperparathyroidism, potentially contributing to accelerated bone resorption ([@R10]). Vitamin D deficiency and associated secondary hyperparathyroidism may represent a modifiable risk factor for fractures among individuals with SCI and SLOP.

Currently, there is no universal definition of an optimal serum 25(OH)D level for bone health. Serum 25(OH)D levels between 78 and 80 nmol/L have been proposed for maximizing calcium absorption and suppressing PTH, and it has been suggested that a minimum vitamin D intake of 1,000IU per day is needed to achieve this ([@R11]). Data suggests that vitamin D intake is not sufficient among individuals with SCI; even in those who achieve an adequate intake ([@R12]). Bauman and colleagues ([@R10]) demonstrated that after daily supplementation with 800 IU of vitamin D for 12 months, 9 of 40 participants were still 25(OH)D deficient (\<40 nmol/L), and only 8 participants reached levels greater than 75 nmol/L. It is unclear if the proposed guidelines for vitamin D sufficiency and intake for the general population ([@R13]) are sufficiently high to adequately suppress PTH in the SCI population.

The primary purpose of this study was to identify the proportion of individuals with chronic SCI that have suboptimal vitamin D status (serum 25(OH)D \<75 nmol/L) and the proportion that have secondary hyperparathyroidism (Intact PTH ≥ 7.0 pmol/L). Additionally, we aimed to identify correlates of suboptimal vitamin D status in those with chronic SCI. Secondary goals were to evaluate the relationships between serum PTH and serum 25(OH)D, as well as between serum PTH and serum ionized calcium and serum C-telopeptide of type I collagen (CTX-I), a marker of bone resorption.

MATERIALS AND METHODS {#S8}
=====================

Setting and Study Population {#S9}
----------------------------

The primary and secondary research questions were addressed using baseline data from two longitudinal studies being conducted by the University of Waterloo and the Toronto Rehabilitation Institute. Assessments were completed between April 2009 and December 2011. To ensure neurologic stability, only individuals who were ≥24 months post-injury were eligible to participate. To establish a representative sample of the SCI population, males and females with a spinal cord impairment (C1-L2 AIS A-D) of sudden onset, and either a motor complete (AIS A and B) or motor incomplete (AIS C and D) injury were recruited. Individuals were excluded from the study if they had current or prior conditions other than SCI known to influence bone metabolism. Participants were recruited primarily from: a) the Jousse Long-term Follow-up Database; and b) Outpatient services at Lyndhurst Centre. Baseline data from participants in an ongoing clinical trial (n=10) at our centre were included in the current analysis; however, these participants contributed vitamin D levels only.

Outcome Assessments {#S10}
-------------------

### Medical History and Demographics {#S11}

Questionnaires were completed via interview to record past and current medical health status, medication use, lifestyle and demographic data, fracture history, and information related to the SCI. Medical history and impairment descriptors were also abstracted from the patient's medical record. A physiatrist (B.C. Craven) determined the participants' neurologic level of injury and American Spinal Cord Injury Association Impairment Scale (AIS) using the International Standards for the Neurologic Classification of SCI ([@R14]). Height, weight, waist circumference, calcium intake, and supplement use were recorded.

### Blood Collection for Serum Analysis {#S12}

Blood collection was performed by a trained phlebotomist. Participants fasted for at least 12 hours prior to blood collection. Blood samples were drawn using a closed, sterile Vacutainer® system. The collected samples were placed on ice and sent to the Research Laboratory at Mt. Sinai Hospital for immediate analysis.

Serum 25(OH)D was determined with a chemiluminescent immunoassay (CLIA) using the DiaSorin LIAISON® instrument as the platform (DiaSorin, Stillwater, MN); which exhibits 100% cross-reactivity for both 25(OH)D~2~ and 25(OH)D~3~ to estimate the total 25(OH)D circulating in the body ([@R15]).

PTH was determined with an electrochemiluminescent immunoassay (ECLIA) using the Roche Elecsys 1010/2010 and modular analytics E170 immonoassay analyzers (Roche Diagnostics, Mannheim, Germany).

Serum ionized calcium concentration was determined using potentiometers (ABL 735 Analyzer) to relate the electrical potential of the ionized calcium in the serum sample to its concentration using the Nernst equation. Serum CTX-I was measured with an ECLIA on the Roche Elecsys 1010/2010 and modular analytics E170 immonoassay analyzer (Roche Diagnostics, Mannheim, Germany).

Statistical Analyses {#S13}
--------------------

Participant characteristics, including serum 25(OH)D levels and PTH levels were summarized using descriptive statistics: mean (standard deviation) for continuous variables and count (percent) for categorical variables. Vitamin D levels were categorized as suboptimal (\<75 nmol/L) or optimal (≥75 nmol/L). Serum PTH was characterized as normal (1.6 -- 6.9 pmol/L) or above the upper limit of the normal range (≥7 pmol/L). Univariate logistic regression analyses were performed to identify whether the following characteristics were associated with suboptimal vitamin D status: time of year, age, gender, injury level, injury completeness, duration of injury, and supplement use. Additional characteristics assessed include: bisphosphonate use, and smoking status. Odds ratios, 95% confidence intervals (CI), and p values were reported.

Pearson correlation analyses were performed to evaluate the relationships between serum PTH and serum 25(OH)D, and between serum PTH and ionized calcium, as well as between serum PTH and CTX-I and between serum 25(OH)D and CTX-I. Correlation coefficients (r) and p values were reported for all correlation analyses. A value of p\<0.05 was considered significant. All analyses were done with SAS version 9.1 (Cary, North Carolina).

We certify that all applicable institutional and governmental regulations concerning the ethical use of human volunteers were followed during the course of this research.

RESULTS {#S14}
=======

Recruitment and Sample Size {#S15}
---------------------------

Sixty-five individuals were recruited to participate in the current study. Sixty-two 25(OH)D, 53 PTH, 55 ionized calcium, and 53 CTX-I measurements were included in the final analyses. Reasons for missing data include; difficulties with blood draw during baseline visit, errors in processing at the analysis lab, vitamin D levels available only, and participants declining the blood draw.

Participant Characteristics {#S16}
---------------------------

All participants acquired their SCI from a traumatic event, and were at least two years post injury. The cohort consisted of 51 male and 14 female participants, with a mean age of 49 (±12) years. At the time of assessment, 86% of participants were taking vitamin D supplements, and 75% of participants were taking calcium supplements ([Table 1](#T1){ref-type="table"}). The range of vitamin D supplement doses consumed was from 200 IU to 5000 IU per day, with two individuals reporting taking 50 000 IU weekly at some point in the past year. Forty one percent were taking at least 1,000IU per day not including a multivitamin. If one assumes that a multivitamin contains 250IU or 400IU of vitamin D, two additional individuals (or 45% of the sample) were taking at least 1,000IU/day of vitamin D.

Serum Vitamin D, PTH, Ionized Calcium and CTX-I {#S17}
-----------------------------------------------

Sixty-one percent (95% CI, 49 -- 73) of the population had serum 25(OH)D levels in the optimal range ([Table 2](#T2){ref-type="table"}). The mean (SD) serum 25(OH)D level and the 95% confidence intervals within the suboptimal category was 52.9 (± 15.8) nmol/L (95% CI, 46.2 -- 59.6), whereas that in the optimal category was 107.9 (± 31.7) nmol/L (95% CI, 97.5 -- 118.3). If we used \<50nmol/L as a cut-off, 10% of our sample would have vitamin D insufficiency.

Eighty-seven percent (95% CI, 78 -- 96) of the population demonstrated serum intact PTH levels within the normal range ([Table 2](#T2){ref-type="table"}). The mean (SD) serum intact PTH level within the normal hormonal range was 3.8 (±1.4) pmol/L (95% CI, 3.3 -- 4.2), whereas the mean (SD) serum intact PTH level in the group with secondary hyperparathyroidism was 9.0 (±2.4) pmol/L (95% CI, 6.8 -- 11.2). Additionally, the 25(OH)D level above which all individuals were classified as having normal PTH was around 95 nmol/L.

Three individuals (6%) of group had both suboptimal vitamin D and elevated PTH. Only one of the seven individuals with elevated PTH was not taking 1000mg of calcium daily, and that person was taking 400mg. That same individual was the only one who was not taking supplemental vitamin D; all others were taking 750IU or greater. The mean (SD) of serum ionized calcium for the whole cohort was 1.24 (±0.04) mmol/L ([Table 2](#T2){ref-type="table"}.). The mean (SD) of serum CTX-I was 263.6 (±145.2) ng/L.

Correlates of Suboptimal Vitamin D Status {#S18}
-----------------------------------------

Univariate logistic regression analyses were performed to identify population characteristics associated with vitamin D deficiency ([Table 3](#T3){ref-type="table"}). Those with vitamin D assessments performed in the winter months (OR=7.38, C.I.=2.30--23.65, p=0.001), and those not taking vitamin D (OR=7.41, C.I.=1.39--39.53, p=0.019) or calcium (OR=7.19, C.I.=1.94--26.68, p=0.003) supplements had an increased odds of being vitamin D deficient. Additionally, younger age (OR=0.932, C.I.=0.88--0.98, p=0.010), not being on bisphosphonate therapy (OR=3.85, C.I.=1.30--11.34, p=0.015) and having paraplegia (vs. tetraplegia) (OR=4.22, C.I.=1.31--13.65, p=0.016) were associated with vitamin D deficiency.

Relationship between PTH and 25(OH)D and Calcium {#S19}
------------------------------------------------

There was a significant correlation between serum intact PTH and serum 25(OH)D levels (r=−0.304, p=0.032) ([Figure 1](#F1){ref-type="fig"}). Additionally, there was a significant positive correlation between serum CTX-I and serum intact PTH (r=0.308, p=0.025) ([Figure 2](#F2){ref-type="fig"}).

DISCUSSION {#S20}
==========

Although a large proportion of our sample reported vitamin D and multivitamin use, 39% of the study population with chronic SCI presented with serum 25(OH)D levels in the suboptimal range (\<75 nmol/L), and 13% had secondary hyperparathyroidism. Additionally, having 25(OH)D assessed in the winter months, lack of a calcium or vitamin D supplement use, younger age, lack of bisphosphonate use and injury level were associated with suboptimal 25(OH)D serum levels. A novel finding of our work was that secondary hyperparathyroidism was associated with lower serum 25(OH)D and increased bone resorption (CTX-I), suggesting that disruption of the vitamin D -- PTH axis may be a contributor to excess resorption and declining bone mass in the chronic SCI population.

Thirty-nine percent of the individuals with chronic SCI studied demonstrated suboptimal 25(OH)D levels (\<75nmol/L). One previous report of vitamin D status in the SCI population similarly identified more than 32% of participants with suboptimal serum 25(OH)D levels ([@R10]); however, deficiency was defined as \<40nmol/L. Recently, Oleson and colleagues ([@R16]) identified 96% of participants with chronic SCI as Vitamin D deficient (\<80nmol/L). However, they excluded individuals consuming greater than 400IU of vitamin D per day, which may overestimate the prevalence of deficiency. Another study of vitamin D status in individuals with SCI, found 93% to have inadequate (\<75nmol/L) 25(OH)D levels ([@R9]), but this study was limited to an inpatient rehabilitation setting of acutely injured patients. We have reported the vitamin D status of men and women with chronic SCI who residing in the community, with diverse impairments. Given many of the current study population were recruited from an osteoporosis clinic and were being monitored annually, the true prevalence of vitamin D deficiency in the SCI population may be closer to that in observed in the general population of post-menopausal women, which has been estimated as 64% ([@R17]). Of the 39% found to have suboptimal serum 25(OH)D in the current study, 71% reported being on a vitamin D supplement, demonstrating that despite taking supplements, serum 25(OH)D concentrations are not reaching or not remaining at optimal levels over time. Therefore, serum 25(OH)D should be monitored over time after SCI, and the dosage of vitamin D prescribed titrated on an individual basis.

A novel observation in the current study was a significant positive relationship between serum CTX-I and serum intact PTH, identifying that higher PTH levels are associated with greater bone resorption, which is a modifiable risk factor for osteoporotic fracture in chronic SCI. The presence of secondary hyperparathyroidism may be associated with low vitamin D levels in chronic SCI ([@R10]). An inverse relationship between serum 25(OH)D and intact PTH has been demonstrated in older persons without SCI ([@R18], [@R19]), and in individuals with long-standing SCI ([@R10]). Among older adults in a residential care setting, hyperparathyroidism in the presence of low vitamin D levels was associated with higher bone turnover and an increased risk of mortality, however not all older adults with low vitamin D levels had a hyperparathyroid response, suggesting that some individuals may be more susceptible than others ([@R20]). Among our cohort 13% had serum PTH above the upper limit of normal, whereas 39% had suboptimal vitamin D levels. The threshold of vitamin D needed in the general population to maximally suppress PTH release was shown to be as high as 80 nmol/L ([@R21]), but it is not known if the threshold is different after SCI. Based on the current study, the data suggest that in those with chronic SCI, the serum 25(OH)D threshold for suppression of PTH is about 94 nmol/L. It would be interesting to evaluate the level of 25(OH)D at which the PTH plateaus in a larger sample of individuals with chronic SCI. Our work suggests that serial monitoring of vitamin D, PTH and C-TX is necessary to prevent increased bone resorption among individuals with chronic SCI.

The following correlates of suboptimal vitamin D status in individuals with chronic SCI were identified in this study: youth, lack of a calcium or vitamin D supplement, assessment of vitamin D during the winter months, lack of bisphosphonate use and paraplegia. Our findings emphasize that many individuals with SCI are not acquiring enough vitamin D through sun exposure or diet. Opperman ([@R22]) reported vitamin D and calcium to be in the top three supplements used in the SCI population, and given that vitamin D is often prescribed in conjunction with calcium, it is not surprising that lack of calcium supplementation is associated with vitamin D deficiency. Interestingly, being younger and having paraplegia (versus tetraplegia) were associated with an increased odds of suboptimal serum 25(OH)D levels. Vitamin D metabolism in younger individuals with SCI may be different to that of older individuals with SCI. Decreased renal function, medications use post-SCI, and history of medication use may affect older and younger individuals differently. That younger age and paraplegia are associated with lower vitamin D status are unique findings, and others have observed the opposite ([@R23]), or that function and associated activity participation are more important correlates. There were 15 individuals aged 40 or younger in the current study. Therefore, we suggest that our findings be used for hypothesis-generating purposes in larger studies. Further, it is clear that vitamin D deficiency may be present despite use of vitamin D supplements and therefore individuals using supplements should not be excluded from studies examining correlates of vitamin D deficiency or the relationship between PTH and bone turnover. The current results do help identify intervention targets for clinicians based on clinical history (e.g., supplement use) and season of assessment. Routine monitoring of supplement adherence and titration of serum levels into the optimal range is required to optimize bone health, thereby minimizing or eliminating increases in PTH and maximizing absorption of calcium, magnesium and phosphate.

Several study limitations should be acknowledged. We were unable to distinguish between newly occurring, recent or longstanding suboptimal vitamin D levels with the current study design. Additionally, other medications known to effect vitamin D metabolism, such as anticonvulsants, sex hormone levels, as well as sun exposure, and supplement adherence were not considered in the current analysis. Others have reported considerable seasonal variation in 25(OH)D levels among young people in the general population without SCI living in a similar catchment to those included in this study ([@R24]). We attempted to account for sun exposure by looking at season as a risk factor. Many participants were recruited via physician referral from an outpatient osteoporosis clinic, thereby introducing recruitment bias. However, prevalence of suboptimal 25(OH)D in a non-SCI population has been shown to be independent of whether or not persons were on prescription osteoporosis treatment ([@R25]). The average age of our participants was 50 years, therefore typical "young people" with SCI are under-represented. Although there are some factors affecting the external validity, there is no other literature evaluating vitamin D status in a similarly well-represented cohort (gender and impairment strata) of individuals with chronic SCI. Future studies should include strategies for accurately reflecting fluctuations in 25(OH)D levels over time in the study design and analysis.

CONCLUSIONS {#S21}
===========

Disruption of the vitamin D-PTH axis is likely an important contributor to declines in hip and knee region bone mineral density observed in the chronic SCI population. The negative association between vitamin D levels \[25(OH)D\] and PTH has been described amply in the general population and has been reported previously in those with SCI, but the positive association between PTH and markers of bone turnover is a new, confirmatory finding. Monitoring of Serum 25(OH)D levels is crucial among persons with chronic SCI to maintain normal PTH levels and attenuate increased bone turnover. Thirty-nine percent of the population studied demonstrated suboptimal vitamin D levels, despite a large proportion taking vitamin D and calcium supplements. Identified risk factors for suboptimal vitamin D levels in the SCI population include: younger age, lack of a calcium or vitamin D supplement, testing during the winter months, lack of bisphosphonate use and paraplegia.
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###### 

Participant characteristics/descriptors

                                                                             Male           Female         Total
  -------------------------------------------------------------------------- -------------- -------------- --------------
  **Total n**                                                                51             14             65
  **Age (years)**[\*](#TFN1){ref-type="table-fn"}                            49 (±12)       50 (±13)       50 (±12)
  **Height (cm)**[\*](#TFN1){ref-type="table-fn"}                            178.2 (±8.5)   166.7 (±6.7)   175.6 (±9.4)
  **Weight (kg)**[\*](#TFN1){ref-type="table-fn"}                            83.8 (±17.6)   70.4 (±16.1)   80.7 (±18.0)
  **Injury Characteristics**                                                                               
   **Motor Complete Paraplegia (n)**                                         22             6              28
   **Motor Incomplete Paraplegia (n)**                                       8              2              10
   **Motor Complete Tetraplegia (n)**                                        12             3              15
   **Motor Incomplete Tetraplegia (n)**                                      9              3              12
   **Time Post-Injury (years)**[\*](#TFN1){ref-type="table-fn"}              13.8 (±10.1)   18.4 (±8.8)    14.8 (±10.0)
  **On vitamin D supplement**[†](#TFN2){ref-type="table-fn"}                 42 (82%)       14 (100%)      56 (86%)
  **On calcium supplement**[†](#TFN2){ref-type="table-fn"}                   36 (71%)       13 (93%)       49 (75%)
  **On multivitamin**[†](#TFN2){ref-type="table-fn"}                         22 (43%)       9 (64%)        31 (48%)
  **On bisphosphonate therapy**[†](#TFN2){ref-type="table-fn"}               26 (51%)       8 (57%)        34 (52%)
  **Current smoker**[†](#TFN2){ref-type="table-fn"}                          15 (29%)       4 (29%)        19 (29%)
  **Summer Assessment (May -- October)**[†](#TFN2){ref-type="table-fn"}      33 (65%)       8 (57%)        41 (63%)
  **Winter Assessment (November -- April)**[†](#TFN2){ref-type="table-fn"}   18 (35%)       6 (43%)        24 (37%)

Values are mean (±SD),

Values are n(%)

###### 

Serum results

  -------------------------------------------------------------------------------------------------------------------------------------------
  Serum Measurement          n    Normal/Optimal Range        Mean (±SD), 95% C.I.             Range           \% in Normal Range, 95% C.I.
  -------------------------- ---- --------------------------- -------------------------------- --------------- ------------------------------
  25(OH)D (nmol/L)           62   \>75                        86.6 (±37.8), 76.9 -- 96.2       15 -- 226       61%, 49 -- 73%

  Intact PTH (pmol/L)        53   1.6 -- 6.9                  4.4 (±2.4), 3.8 -- 5.1           1.9 -- 13.6     87%, 78 -- 96%

  Ionized calcium (mmol/L)   55   1.17 -- 1.33                1.24 (±0.04), 1.23 -- 1.25       1.08 -- 1.34    96%, 91 -- 100%

  CTX-I (ng/L)               53   Men: 90 -- 750\             263.6 (±145.2), 223.6 -- 303.7   45.0 -- 701.0   Men: 95%, 88 -- 100%\
                                  PreM. Women: 50 -- 900\                                                      PreM. W: 100%, N/A\
                                  PostM. Women: 210 -- 1100                                                    PostM. W: 50%, 10 -- 90%
  -------------------------------------------------------------------------------------------------------------------------------------------

PreM. = Pre-menopausal; PostM. = Post-menopausal

###### 

Odds ratios of characteristics associated vitamin D deficiency (n=62)

  Characteristic                      OR      95% CI          p value
  ----------------------------------- ------- --------------- ---------------------------------------
  Winter months (November -- April)   7.38    2.30 -- 23.65   0.001[\*](#TFN4){ref-type="table-fn"}
  Female                              0.460   0.11 -- 1.91    0.285
  Age                                 0.932   0.88 -- 0.98    0.010[\*](#TFN4){ref-type="table-fn"}
  Time post injury                    0.962   0.91 -- 1.02    0.170
  Motor complete injury               0.679   0.23 -- 2.01    0.484
  Paraplegic                          4.22    1.31 -- 13.65   0.016[\*](#TFN4){ref-type="table-fn"}
  Not on a vitamin D supplement       7.41    1.39 -- 39.53   0.019[\*](#TFN4){ref-type="table-fn"}
  Not on a calcium supplement         7.19    1.94 -- 26.68   0.003[\*](#TFN4){ref-type="table-fn"}
  Not on a multivitamin               0.982   0.35 -- 2.77    0.973
  Not on bisphosphonate therapy       3.85    1.30 -- 11.34   0.015[\*](#TFN4){ref-type="table-fn"}
  Current smoker                      2.68    0.87 -- 8.25    0.086

Significant (p\<0.05)
